SEARCH

SEARCH BY CITATION

References

  • 1
    Bernard P, Vaillant L, Labeille B et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 1995; 131: 4852.
  • 2
    Marazza G, Pham HC, Scharer L et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861868.
  • 3
    Stanley JR, Hawley-Nelson P, Yuspa SH et al. Characterization of bullous pemphigoid antigen: a unique basement membrane protein of stratified squamous epithelia. Cell 1981; 24: 897903.
  • 4
    Stanley JR, Tanaka T, Mueller S et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J Clin Invest 1988; 82: 18641870.
  • 5
    Guo L, Degenstein L, Dowling J et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 1995; 81: 233243.
  • 6
    Thoma-Uszynski S, Uter W, Schwietzke S et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 2004; 122: 14131422.
  • 7
    Skaria M, Jaunin F, Hunziker T et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230. J Invest Dermatol 2000; 114: 9981004.
  • 8
    Hall RP III, Murray JC, McCord MM et al. Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 1993; 101: 914.
  • 9
    Kiss M, Husz S, Janossy T et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 2005; 24: 110.
  • 10
    Diaz LA, Ratrie H III, Saunders WS et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest 1990; 86: 10881094.
  • 11
    Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol 1992; 99: 243250.
  • 12
    Hopkinson SB, Riddelle KS, Jones JC. Cytoplasmic domain of the 180-kD bullous pemphigoid antigen, a hemidesmosomal component: molecular and cell biologic characterization. J Invest Dermatol 1992; 99: 264270.
  • 13
    Bedane C, McMillan JR, Balding SD et al. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida. J Invest Dermatol 1997; 108: 901907.
  • 14
    Ishiko A, Shimizu H, Kikuchi A et al. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin. J Clin Invest 1993; 91: 16081615.
  • 15
    Nonaka S, Ishiko A, Masunaga T et al. The extracellular domain of BPAG2 has a loop structure in the carboxy terminal flexible tail in vivo. J Invest Dermatol 2000; 115: 889892.
  • 16
    Giudice GJ, Emery DJ, Zelickson BD et al. Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. J Immunol 1993; 151: 57425750.
  • 17
    Zillikens D, Rose PA, Balding SD et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol 1997; 109: 573579.
  • 18
    Nakatani C, Muramatsu T, Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol 1998; 139: 365370.
  • 19
    Zillikens D, Mascaro JM, Rose PA et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 1997; 109: 679683.
  • 20
    Dopp R, Schmidt E, Chimanovitch I et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 2000; 42: 577583.
  • 21
    Haase C, Budinger L, Borradori L et al. Detection of IgG autoantibodies in the sera of patients with bullous and gestational pemphigoid: ELISA studies utilizing a baculovirus-encoded form of bullous pemphigoid antigen 2. J Invest Dermatol 1998; 110: 282286.
  • 22
    Sitaru C, Schmidt E, Petermann S et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal–epidermal separation in cryosections of human skin. J Invest Dermatol 2002; 118: 664671.
  • 23
    Tsuji-Abe Y, Akiyama M, Yamanaka Y et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 2005; 37: 145149.
  • 24
    Bernard P, Reguiai Z, Tancrede-Bohin E et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145: 537542.
  • 25
    Hofmann S, Thoma-Uszynski S, Hunziker T et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119: 10651073.
  • 26
    Anhalt GJ, Diaz LA. Animal models for bullous pemphigoid. Clin Dermatol 1987; 5: 117125.
  • 27
    Sams WM Jr, Gleich GJ. Failure to transfer bullous pemphigoid with serum from patients. Proc Soc Exp Biol Med 1971; 136: 10271031.
  • 28
    Anhalt GJ, Labib RS, Voorhees JJ et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 11891196.
  • 29
    Liu Z, Diaz LA, Troy JL et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 1993; 92: 24802488.
  • 30
    Liu Z, Giudice GJ, Swartz SJ et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995; 95: 15391544.
  • 31
    Chen R, Ning G, Zhao ML et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 2001; 108: 11511158.
  • 32
    Liu Z, Giudice GJ, Zhou X et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 1997; 100: 12561263.
  • 33
    Olasz EB, Roh J, Yee CL et al. Human bullous pemphigoid antigen 2 transgenic skin elicits specific IgG in wild-type mice. J Invest Dermatol 2007; 127: 28072817.
  • 34
    Lanschuetzer CM, Olasz EB, Lazarova Z et al. Transient anti-CD40L co-stimulation blockade prevents immune responses against human bullous pemphigoid antigen 2: implications for gene therapy. J Invest Dermatol 2009; 129: 12031207.
  • 35
    Nishie W, Sawamura D, Goto M et al. Humanization of autoantigen. Nat Med 2007; 13: 378383.
  • 36
    Wang G, Ujiie H, Shibaki A et al. Blockade of autoantibody-initiated tissue damage by using recombinant Fab antibody fragments against pathogenic autoantigen. Am J Pathol 2010 (in press).
  • 37
    Nishie W, Sawamura D, Natsuga K et al. A novel humanized neonatal autoimmune blistering skin disease model induced by maternally transferred antibodies. J Immunol 2009; 183: 40884093.
  • 38
    Liu Z, Sui W, Zhao M et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008; 31: 331338.
  • 39
    Provost TT, Tomasi TB Jr. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol 1974; 18: 193200.
  • 40
    Friedmann PS. Assessment of urticaria and angio-oedema. Clin Exp Allergy 1999; 29 (Suppl 3): 109112.
  • 41
    Dimson OG, Giudice GJ, Fu CL et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 2003; 120: 784788.
  • 42
    Iwata Y, Komura K, Kodera M et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol 2008; 144: 4148.
  • 43
    Dresow SK, Sitaru C, Recke A et al. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol 2009; 160: 429432.
  • 44
    Zone JJ, Taylor T, Hull C et al. IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. J Invest Dermatol 2007; 127: 11671174.
  • 45
    Fairley JA, Burnett CT, Fu CL et al. A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu/nu mice. J Invest Dermatol 2007; 127: 26052611.
  • 46
    Fairley JA, Baum CL, Brandt DS et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123: 704705.